Recent breakthroughs in cancer treatment have seen scientists engineering cancer-fighting immune cells directly within the body. Azalea Therapeutics is making significant strides with its innovative in vivo CAR-T therapy, which includes methods for site-specific TRAC-CAR T cell engineering. The new strategies developed allow for the generation of CAR-T cells inside the body, using a dual-vector system and an injectable approach to reprogram T cells for targeting tumors. These transformative methods promise to attack cancer from within, emphasizing the potential of personalized and precise therapeutic solutions. Notable publications, including a recent one in Nature, highlight the transformative impact of these technologies in revolutionizing cancer care.